Literature DB >> 19060851

Ustekinumab poised to enter the psoriasis market.

Charlie Schmidt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060851     DOI: 10.1038/nbt1208-1317a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Biocon's first-in-class anti-CD6 mAb reaches the market.

Authors:  Killugudi Jayaraman
Journal:  Nat Biotechnol       Date:  2013-12       Impact factor: 54.908

2.  Immunology's quiet upheaval.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2009-08       Impact factor: 54.908

3.  Psoriasis: Is ustekinumab superior to etanercept for psoriasis?

Authors:  Annegret Kuhn; Thomas A Luger
Journal:  Nat Rev Rheumatol       Date:  2010-09       Impact factor: 20.543

4.  Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells.

Authors:  Milan Kuchař; Lucie Vaňková; Hana Petroková; Jiří Cerný; Radim Osička; Ondřej Pelák; Hana Sípová; Bohdan Schneider; Jiří Homola; Peter Sebo; Tomáš Kalina; Petr Malý
Journal:  Proteins       Date:  2013-11-23

Review 5.  Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.

Authors:  Chao-Yang Lai; Yu-Wen Su; Kuo-I Lin; Li-Chung Hsu; Tsung-Hsien Chuang
Journal:  J Immunol Res       Date:  2017-08-13       Impact factor: 4.818

Review 6.  The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.

Authors:  Shalki Choudhary; Kajal Sharma; Om Silakari
Journal:  Microb Pathog       Date:  2020-12-02       Impact factor: 3.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.